Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2016-11-12 Legal Proceedings Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
SITC 2016 : Présentation de données cliniques
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 8, 2016, announcing intermediate clinical efficacy data from a Phase I/II study (CA223-001) testing the combination of lirilumab and nivolumab for head and neck cancer. It details response rates (ORR), safety profiles, and quotes management/investigators regarding the results, which were presented at the SITC conference. This content structure—announcing clinical trial results, providing key data points, and discussing future development—is characteristic of an Earnings Release (ER) or a specific clinical update. Since it focuses purely on the results of a clinical trial and is presented as a formal announcement by the pharmaceutical companies (Bristol-Myers Squibb and Innate Pharma), it aligns best with the 'Earnings Release' (ER) category, which often includes key operational/clinical milestones announced outside of standard quarterly financial reporting, or potentially an 'Interim Report' (IR) if it were a comprehensive filing. However, given the format is a press release announcing specific trial data points and quotes, 'ER' (Earnings Release, often used broadly for key results announcements) is the most fitting category among the choices, as it is not a full financial report (10-K/IR) or a presentation deck (IP). It is a release of key performance indicators (clinical efficacy).
2016-11-12 French
SITC 2016 : Clinical Data Release
Investor Presentation Classification · 95% confidence The document text is a press release announcing interim clinical trial data for a combination therapy (Lirilumab and Opdivo) in advanced cancer patients. It details efficacy results (ORR), safety profiles, study design (Phase 1/2), and provides background information on the drugs and the disease. This content structure—announcing clinical trial results, often presented at a medical conference (SITC Annual Meeting), and issued by pharmaceutical companies—is characteristic of an announcement related to ongoing research and development, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). It is not a standard regulatory filing (10-K, AR, IR, ER). It is not a management discussion (MDA) or a formal presentation (IP). Since it is a press release announcing specific clinical data and study progress, it most closely aligns with an Investor Presentation (IP) if it were a slide deck, or potentially a Regulatory Filing (RNS) if it were a general announcement. However, given the detailed nature of the clinical data disclosure, it functions as an Investor Presentation of data, even if it's structured as a press release. In the context of the provided definitions, this type of detailed clinical data disclosure, often shared with investors and analysts, fits best under Investor Presentation (IP), which covers detailed focus on financials, strategy, and market position (clinical progress being a key part of market position for a biotech/pharma company). It is not a short announcement of a report being available (RPA/RNS).
2016-11-12 English
InnInvestor conference call on November 14, 2016
Report Publication Announcement Classification · 99% confidence The document text is titled "INNATE PHARMA INVESTOR CONFERENCE CALL ON NOVEMBER 14, 2016 TO DISCUSS RECENT NEW CLINICAL DATA" and explicitly states that the company "will host a conference call for institutional investors and sell-side analysts to discuss recent clinical data." It provides the exact date, time, dial-in numbers, and speakers for this event. This content perfectly matches the definition of a Call Transcript (CT), although this specific document is the *announcement* of the call, not the transcript itself. However, among the provided options, 'Call Transcript (CT)' is the most appropriate category for materials directly related to a scheduled conference call, especially when the content is focused on the discussion points (clinical data). Given the context of financial reporting, announcements about earnings/investor calls are often grouped with the call materials. Since it is an announcement *about* a call, it could potentially be RPA or RNS, but the subject matter is so specific to a conference call that CT is the strongest fit for the *topic* being addressed. Since the document is long (over 10k characters) and details the content to be discussed, it is more than just a brief announcement of a report (RPA/RNS). It is the preparatory material for a conference call.
2016-11-10 English
Conférence téléphonique investisseur le 14 nov. 2016
Report Publication Announcement Classification · 99% confidence The document is a press release dated November 10, 2016, announcing that Innate Pharma will hold an investor conference call on November 14, 2016, to discuss recent clinical data presented at various medical congresses (SITC, ESMO, 3WCCL). It details the speakers, dial-in information, and provides summaries of the data presented or to be presented regarding their drug candidates (lirilumab, IPH4102, Monalizumab). This content—announcing a call to discuss recent results and strategy—is characteristic of an Investor Presentation (IP) or a general update, but the primary focus is the announcement of a specific event (the conference call) where management will discuss clinical data and strategy. Since it is an announcement about an upcoming event where detailed information will be shared, and it contains substantial strategic and clinical data summaries, it aligns best with an Investor Presentation (IP) or potentially an Earnings Release (ER) if it were tied to quarterly results, but here it is explicitly about clinical data updates. Given the detailed discussion of clinical trial data and future presentations, 'Investor Presentation' (IP) is the most fitting category, as it serves the purpose of informing investors about scientific progress, even if delivered via a call rather than a static deck.
2016-11-10 French
PRELIMINARY PHASE 1/2 EFFICACY DATA SITC 2016
Regulatory Filings Classification · 90% confidence The document is a press release dated November 8, 2016, announcing the publication of preliminary efficacy data for a drug combination (Lirilumab and Opdivo) that will be presented at the SITC meeting. It details the clinical results (ORR, DCR), provides background on the drug and the disease, and crucially, announces a future conference call for investors to discuss these data. The document itself is not the full financial report (10-K or IR), nor is it solely a management discussion (MDA) or an earnings release (ER). It is an announcement of scientific/clinical data and an upcoming investor call. Since it is a formal announcement of clinical trial results and includes details about an upcoming investor call, it functions as a general corporate update related to R&D progress. Given the options, this type of announcement, which is not a standard financial filing, dividend notice, or management change, fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate disclosure, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the data presentation and a call. Since it is a press release detailing scientific findings and announcing an investor call, RNS is the most appropriate general disclosure category when a more specific scientific/clinical filing code is unavailable. It is not short enough to strictly qualify as an RPA based on the 'Menu vs Meal' rule, as it contains substantial content about the data and the trial itself.
2016-11-08 English
DONNÉES PRÉLIMINAIRES SITC 2016
Report Publication Announcement Classification · 98% confidence The document is a press release dated November 8, 2016, announcing preliminary efficacy data from a Phase I/II study presented at the SITC conference. It details clinical results (ORR, DCR) for a combination therapy (Lirilumab with Nivolumab) and announces an upcoming investor conference call on November 14, 2016, to discuss these results. The text explicitly states that the detailed data will be presented orally at the SITC conference and that management will present a summary during the conference call. Crucially, it mentions that the presentation slide deck will be available 15 minutes before the call. This structure—announcing results that were presented elsewhere and scheduling a follow-up call with materials to be released shortly before the call—strongly indicates this document serves as an announcement regarding the publication or presentation of results, rather than being the full financial report (10-K, IR) or the transcript of the call itself (CT). Therefore, it fits best under Report Publication Announcement (RPA).
2016-11-08 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.